Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

Emergence of clinical resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clinical responses in melanoma. Inhibiting HSP90 offers an approach to simultaneously interfere with multiple resistance mechanisms. Using the HSP90 inhibitor, AT13387, which is currently in clin...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Cancer Ther
Main Authors: Smyth, Tomoko, Paraiso, Kim H T, Hearn, Keisha, Rodriguez-Lopez, Ana M, Munck, Joanne M, Haarberg, H Eirik, Sondak, Vernon K, Thompson, Neil T, Azab, Mohammad, Lyons, John F, Smalley, Keiran S M, Wallis, Nicola G
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263034/
https://ncbi.nlm.nih.gov/pubmed/25349308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0452
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker